Share on StockTwits

XenoPort (NASDAQ:XNPT) Director Cathy Friedman purchased 2,600 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were purchased at an average price of $3.92 per share, with a total value of $10,192.00. Following the acquisition, the director now directly owns 12,300 shares in the company, valued at approximately $48,216. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

XenoPort (NASDAQ:XNPT) traded up 6.68% on Wednesday, hitting $4.31. The stock had a trading volume of 150,107 shares. XenoPort has a 52-week low of $3.15 and a 52-week high of $7.20. The stock has a 50-day moving average of $3.98 and a 200-day moving average of $5.26. The company’s market cap is $266.8 million.

XenoPort (NASDAQ:XNPT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.32) by $0.04. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $3.86 million. During the same quarter in the prior year, the company posted ($0.50) earnings per share. The company’s quarterly revenue was up 639.1% on a year-over-year basis. On average, analysts predict that XenoPort will post $-1.46 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on XNPT shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of XenoPort in a research note on Thursday, May 15th. They now have a $6.00 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of XenoPort from $12.00 to $10.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. XenoPort has a consensus rating of “Hold” and an average price target of $6.22.

XenoPort, Inc is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.